Categories: Patents

Supreme Court divided in battle over Teva MS drug patent

Washington – The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical IndustriesLtd’s high-profile fight with generic drug manufacturers overpatent protections for Copaxone, its top-selling multiple sclerosis drug.

Israel-based Teva is battling to protect a key patent for the $4-billion-a-year MS drug that is due to expire in September 2015. Copaxone accounts for 50 percent of Teva profits, and the patent fight is one of the most important business cases of the current term for Supreme Court’s nine justices.

There are two teams developing cheaper generic forms of Copaxone: one involvingNovartis AG’s Sandoz Inc andMomenta Pharmaceuticals Inc and another involving Mylan Incand Natco Pharma Ltd.

The justices appeared unsure over to what extent the U.S. Court of Appeals for the Federal Circuit, which hears all patent appeals, should have leeway to second-guess findings made by a district court judges about patent claim construction , the key issue in the case.

The appeals court ruled in favor of the generic companies, overturning a lower court ruling that had gone Teva’s way.

Several justices, including Chief Justice John Roberts and Justice Samuel Alito, appeared reluctant to tinker with the existing system in which the appeals court is accorded great latitude in rethinking lower court findings.

“Is it worthwhile as a practical matter?” Alito asked, referring to the notion of disrupting the status quo.

Justice Sonia Sotomayor added, “Why don’t we defer, as has been done now forever, to the Federal Circuit?”

Other justices seemed more concerned about the appeals court exerting too much power over lower court judges. Justice Stephen Breyer cited other areas of the law in which lower court judges have discretion.

Federal district judges, unlike appeals court judges, can preside over lengthy hearings and weigh all the evidence firsthand before issuing decisions, which is a “powerful reason for saying in a technical case, ‘Don’t overturn the judge’s factual findings,'” Breyer said.

Justice Elena Kagan made a similar point that under federal law there is a “very blanket rule” that restricts what issues appeals courts can normally review on appeal.

In July 2013, the appeals court ruled the patent was invalid, prompting Teva to seek Supreme Court review. The Supreme Court declined to stay the appeals court ruling pending appeal, meaning Copaxone currently has no patent protection.

With the fate of the patent uncertain, Mylan has said it plans to launch as soon as it has government approval, which could be before the end of 2014. Sandoz and Momenta declined to comment on when they expect their product to be available.

Teva, meanwhile, is switching patients with multiple sclerosis, an often-disabling nervous system disease affecting the brain and spinal cord, who use Copaxone over to a new patent-protected formulation of it.

A ruling is due by the end of June. The case is Teva Pharmaceuticals v. Sandoz, U.S. Supreme Court, No. 13-854. Reuters

The Pharma Times News Bureau

Recent Posts

DKMS-BMST – Bridging the Care Gap in Blood Cancer Treatment on National Cancer Awareness Day

New Delhi, November 07, 2024: National Cancer Awareness Day serves as a poignant reminder of…

7 hours ago

The Arya Vaidya Pharmacy (Coimbatore) Ltd. Strengthens Legacy with New Initiatives and Expanded Product Portfolio

Coimbatore, November 07, 2024: The Arya Vaidya Pharmacy (Coimbatore) Ltd. (AVP), a pioneer in Ayurvedic…

7 hours ago

New medical nutrition ingredient combines high-protein with “best taste yet”

New Delhi, November 06, 2024: Arla Foods Ingredients has launched a new whey protein hydrolysate…

1 day ago

6 Early Signs of Ovarian Cancer

By Dr. C N Patil, HOD and Lead Consultant - Medical Oncology & Haemato-Oncology, Aster…

1 day ago

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

2 days ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

3 days ago